Sanofi’s Sarclisa Treatment Combination Shows More Positive Data on Multiple Myeloma

Sanofi’s monoclonal antibody drug Sarclisa (isatuximab) shows promising late-stage trial data in patients with relapsed multiple myeloma who are in the second-line treatment setting.

The study, which enrolled 302 participants, demonstrated that Sarclisa, in combination with Amgen’s Kyprolis (carfilzomib) and the corticosteroid dexamethasone, improved median progression-free survival compared to Kyprolis and dexamethasone alone. The combination therapy also lengthened the interval between treatment times to 44.9 months compared with 25 months in the Kyprolis and dexamethasone group.

In March 2021, early results from the same trial supported the FDA approval of Sarclisa, when combined with Kyprolis and dexamethasone, for patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.